INTEGRILIN must not be used to treat patients with: − hypersensitivity to the active substance or to any of the excipients − evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days of treatment − history of stroke within 30 days or any history of haemorrhagic stroke − known history of intracranial disease (neoplasm, arteriovenous malformation, aneurysm) − major surgery or severe trauma within past 6 weeks − a history of bleeding diathesis − thrombocytopaenia (< 100,000 cells/mm3) − prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 − severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg on antihypertensive therapy) − severe renal impairment (creatinine clearance < 30 ml/min) or dependency on renal dialysis − clinically significant hepatic impairment − concomitant or planned administration of another parenteral GP IIb/IIIa inhibitor